Histogen Inc. (HSTO)

OTCMKTS: HSTO · Delayed Price · USD
0.170
0.00 (0.00%)
May 23, 2024, 11:33 AM EDT - Market open
Market Cap 726.20K
Revenue (ttm) 19,000
Net Income (ttm) -12.41M
Shares Out 4.27M
EPS (ttm) -3.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 603
Open 0.170
Previous Close 0.170
Day's Range n/a
52-Week Range 0.050 - 0.990
Beta 1.11
Analysts n/a
Price Target n/a
Earnings Date Nov 9, 2023

About HSTO

Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of vari... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Ms. Susan A. Knudson
Employees 7
Stock Exchange OTCMKTS
Ticker Symbol HSTO
Full Company Profile

Financial Performance

In 2022, Histogen's revenue was $3.77 million, an increase of 310.12% compared to the previous year's $919,000. Losses were -$10.48 million, -27.24% less than in 2021.

Financial Statements

News

Histogen Files for Voluntary Chapter 11 Protection to Facilitate Wind-Down, Maximize Share Offering

SAN DIEGO, April 18, 2024 (GLOBE NEWSWIRE) -- Histogen Inc. (HSTO, the “Company” or “Histogen”), a drug development company for treatment of bacterial skin infections, today announced that it has file...

5 weeks ago - GlobeNewsWire

Histogen Announces Second Adjournment of Special Meeting of Stockholders

Meeting Adjourned for a Final Time to January 4, 2024 at 8:00 a.m. PT Potential Estimated Cash Distribution to Shareholders of $0.30 to $0.41 if Dissolution Proposal Approved

5 months ago - GlobeNewsWire

Histogen Announces Adjournment of Special Meeting of Stockholders

SAN DIEGO, Dec. 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (OTC: HSTO) today announced that its special meeting of stockholders (the “Special Meeting”) has been adjourned to Thursday, December 14, 202...

6 months ago - GlobeNewsWire

Histogen Announces Board Approval of Complete Liquidation and Dissolution

SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), today announced that its Board of Directors, after extensive consideration of potential strategic alternatives, has approved...

8 months ago - GlobeNewsWire

Conatus Global Opens the Door for Lucrative Funding from Top Tier Venture Capitalists

London, United Kingdom--(Newsfile Corp. - August 7, 2023) - Charles Karsten's family-office consortium, Conatus Global, opens doors to deals by bringing startups and investors face to face. Two world-...

10 months ago - Newsfile Corp

Histogen to Explore Strategic Alternatives

SAN DIEGO, July 05, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule ...

11 months ago - GlobeNewsWire

Histogen Reports First Quarter 2023 Results and Provides Business Update

Received FDA Clearance of IND Application for Emricasan for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

1 year ago - GlobeNewsWire

Histogen Announces Online Publication in the Journal of Investigative Dermatology

Emricasan Treatment has Therapeutic Effect Against Bacterial Skin Infection in Mice Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and  Inflammatory Diseases SAN DIEGO, ...

1 year ago - GlobeNewsWire

Histogen Announces Exclusive Intellectual Property License Agreement with Johns Hopkins University

Licensed Patents Expected to Provide Freedom to Operate and Exclusivity for Emricasan

1 year ago - GlobeNewsWire

Histogen Announces Issuance of US Patent Covering CTS-2090 Methods of Use

The Newly Issued Patent is Expected to Provide Protection into 2040

1 year ago - GlobeNewsWire

Histogen Reports Year-End 2022 Results and Provides Business Update

Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory D...

1 year ago - GlobeNewsWire

Histogen Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing its pan-caspase and caspase selective inhibitors as treatments fo...

1 year ago - GlobeNewsWire

Amerimmune LLC Maintains Intellectual Property on the COVID-19 Related Use of Caspase Inhibitors as a Result of Histogen Inc. Led Arbitration

MCLEAN, Va.--(BUSINESS WIRE)--Amerimmune LLC is a translational medicine biotechnology firm focused on discovery and rapid development of novel therapies for diseases, including COVID-19.

1 year ago - Business Wire

Histogen Hires Alfred P. Spada Ph.D.

Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory Diseases Pipeline Focus on Pan-Caspase and Caspase Selective Inhibitors for Infectious and Inflammatory D...

1 year ago - GlobeNewsWire

Histogen Reports Third Quarter 2022 Financial Results and Provides Business Update

SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-...

1 year ago - GlobeNewsWire

Histogen Reports Second Quarter 2022 Financial Results and Provides Business Update

Closed $5M Financing in July

1 year ago - GlobeNewsWire

Histogen to Report Second Quarter 2022 Financial Results and Provide Business Update

SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...

1 year ago - GlobeNewsWire

Histogen Announces Closing of $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...

2 years ago - GlobeNewsWire

Histogen Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

SAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...

2 years ago - GlobeNewsWire

Histogen Announces 1-for-20 Reverse Stock Split

SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selecti...

2 years ago - GlobeNewsWire

Histogen to Present at the H.C. Wainwright Global Investment Conference

SAN DIEGO, May 17, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selectiv...

2 years ago - GlobeNewsWire

Histogen Reports First Quarter 2022 Financial Results and Provides Business Update

Received $3.75 Million Payment from Allergan

2 years ago - GlobeNewsWire

CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D.

SAN DIEGO--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions. The updated release reads: PARACRINE ANNOUNCES APPOINTMENT OF BIOTECH VETERAN DAV...

2 years ago - Business Wire

Paracrine Announces Appointment of Biotech Veteran David Crean, Ph.D. to the Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Paracrine, Inc., a company developing its novel cell therapy platform in late-stage clinical trials in advanced wound care, announced today the appointment of David Crean, ...

2 years ago - Business Wire

Histogen to Report First Quarter 2022 Financial Results and Provide Business Update

SAN DIEGO, April 28, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase select...

2 years ago - GlobeNewsWire